Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase

– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types –

– New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges impacting radiopharmaceutical development and patient access –

LOS ANGELES, October 17, 2026--The Prostate Cancer Foundation (PCF) today announced the expansion of its Radiopharmaceutical Think Tank, adding new members and establishing its 2026-2027 agenda, which is focused on accelerating development and patient access of novel radiopharmaceutical drugs for cancer treatment. PCF is announcing the second year Think Tank program in conjunction with the European Association of Nuclear Medicine (EANM) Annual Congress, taking place October 17-21 in Vienna, Austria.

Radiopharmaceuticals have moved beyond their traditional role in specialized diagnostics to become an increasingly important therapeutic approach in cancer care. In prostate cancer, PSMA-targeted radioligand therapy has helped establish the clinical and commercial potential of this treatment approach, while continued development across prostate cancer and other tumor types is expanding the field. As radiopharmaceutical therapies move into earlier stages of disease and become available to larger patient populations, stakeholders from manufacturers and regulators to treatment centers and payers must work together to ensure patients can access these innovative medicines.

"The science around radiopharmaceuticals is moving quickly, and the systems needed to develop and deliver these therapies have to keep pace to optimize their benefits for patients across a broad range of cancers," said Oliver Sartor, M.D., Director of the Translational Oncology Research Program at Tulane University School of Medicine and Chair of the Radiopharmaceutical Think Tank. "The Think Tank brings together medical professionals, government experts, and researchers who are on the leading edge of radiopharmaceutical research and clinical practice to solve challenges that will elevate one of oncology's fastest-growing therapeutic fields."

PCF established the Radiopharmaceutical Think Tank in October 2025 to bring together senior leaders from industry, medicine and other disciplines involved in radiopharmaceutical development and delivery. In its second year, the Think Tank will focus on identifying and prioritizing barriers to radiopharmaceutical development and access, bringing those issues to broader oncology, regulatory and payer communities, working toward potential solutions, and applying lessons from prostate cancer to radiopharmaceutical development across a variety of tumor types.